

**MONOCLONAL ANTIBODIES (MABs) —
ANTI-IL, ANTI-IgE, ANTI-TSLP
PRIOR AUTHORIZATION FORM**



Keystone First

PERFORMRxSM
Next Generation Pharmacy Benefits

(form effective 1/8/2024)

Fax to PerformRxSM at **1-866-497-1387**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # of pages:	
Name of office contact:		Contact's phone number:	LTC facility contact/phone:
PATIENT INFORMATION			
Patient name:		Patient ID #:	DOB:
Street address:			
Apt #:	City/state/zip:		Phone:
PRESCRIBER INFORMATION			
Prescriber name:			
Specialty:		NPI:	State license #:
Street address:			
Suite #:	City/state/zip:		
Phone:		Fax:	
CLINICAL INFORMATION			
Medication requested:		Strength:	
Preferred Medications:		Non-Preferred Medications:	
<input type="checkbox"/> Fasenra Pen <input type="checkbox"/> Tezspire Pen		<input type="checkbox"/> Cinqair Vial	
<input type="checkbox"/> Fasenra Syringe <input type="checkbox"/> Xolair Syringe		<input type="checkbox"/> Nucala 100 mg/ml Syringe	
<input type="checkbox"/> Nucala 100 mg/ml Autoinjector <input type="checkbox"/> Xolair Vial		<input type="checkbox"/> Nucala 100 mg/ml Vial	
<input type="checkbox"/> Nucala 40 mg/0.4 ml Syringe		<input type="checkbox"/> Tezspire Syringe	
Dose and directions:		Quantity:	Duration: _____ months
Diagnosis:		Dx code (<i>required</i>):	Weight: _____ lbs/kg
Has the beneficiary used the requested medication in the past 90 days? Submit documentation.			<input type="checkbox"/> Yes – date of last dose: _____ <input type="checkbox"/> No
Is the requested medication being prescribed by or in consultation with a specialist?			<input type="checkbox"/> Yes <i>Submit documentation of consultation, if applicable.</i> <input type="checkbox"/> No
PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):			
Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:			
NPI#:			
Pharmacy Phone #:		Pharmacy Fax #:	
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.			
INITIAL REQUESTS			
Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.			
For a non-preferred drug in this class: Does the beneficiary have a history of trial and failure of or contraindication or an intolerance to the preferred agents in this class that are approved or medically accepted for treatment of the beneficiary's condition? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred agents in this class.			<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No
1. For treatment of ASTHMA:			
<input type="checkbox"/> Has an asthma severity that is consistent with the FDA-approved indication for the requested medication despite use of maximal therapeutic doses of or has contraindication or an intolerance to the following (check all that apply): <input type="checkbox"/> inhaled glucocorticoid <input type="checkbox"/> long-acting beta-agonist (LABA) <input type="checkbox"/> leukotriene modifier <input type="checkbox"/> other (e.g., tiotropium, theophylline): _____		<input type="checkbox"/> For an anti-IgE MAB (e.g., XOLAIR): <input type="checkbox"/> Has moderate-to-severe persistent asthma induced by an unavoidable perennial allergen (pollen, mold, dust mites, etc.) <input type="checkbox"/> Diagnosis confirmed by positive skin test or radioallergosorbent test (RAST) <input type="checkbox"/> Has a pretreatment serum total IgE measurement of: _____	
<input type="checkbox"/> Will continue to use maximal standard asthma controller medications in addition to the requested medication		<input type="checkbox"/> For an anti-IL MAB (e.g., CINQAIR, FASENRA, NUCALA): <input type="checkbox"/> Has asthma of an eosinophilic phenotype – Absolute blood eosinophil count: _____/mL. Date obtained: _____ <input type="checkbox"/> Has severe asthma	
		<input type="checkbox"/> For an anti-TSLP (e.g., TEZSPIRE): <input type="checkbox"/> Has severe asthma	

INITIAL REQUESTS (continued)

2. For treatment of CHRONIC SPONTANEOUS (IDIOPATHIC) URTICARIA:

- Has a history of urticaria for a period of ≥6 weeks
- Requires use of systemic steroids to control urticarial symptoms
- Tried and failed the maximally tolerated dose of an H1 antihistamine (e.g., cetirizine/levocetirizine, fexofenadine, loratadine/desloratadine) taken for at least two weeks or has a contraindication or an intolerance to H1 antihistamines

3. For treatment of EGPA:

- Has a history of asthma
- Has an absolute blood eosinophil count ≥1000/microliter
- Has a blood eosinophil level >10% of leukocytes
- Has evidence of the following (check all that apply):
 - histopathological evidence of:
 - eosinophilic vasculitis
 - perivascular eosinophilic infiltration
 - eosinophil-rich granulomatous inflammation
 - neuropathy (nerve deficit or conduction abnormality)
 - pulmonary infiltrates, non-fixed
 - sino-nasal abnormality
 - cardiomyopathy
 - glomerulonephritis
 - alveolar hemorrhage
 - palpable purpura
 - positive test for ANCA
- Requires systemic glucocorticoids to maintain remission
- Has a contraindication or an intolerance to systemic glucocorticoids
- Has severe EGPA as defined by national treatment guidelines
 - Tried and failed or has a contraindication or an intolerance to rituximab or cyclophosphamide

4. For treatment of HYPEREOSINOPHILIC SYNDROME (HES):

- Has documented FIP1L1-PDGFRα-negative HES
- Has organ damage or dysfunction
- Has a blood eosinophil count ≥1000/microliter
- Requires or has required systemic glucocorticoids to maintain remission
 - Has a contraindication or an intolerance to systemic glucocorticoids

5. For treatment of NASAL POLYPS:

- Has a history of trial and failure of or contraindication or intolerance to nasal corticosteroids
- For an anti-IgE MAB (e.g., XOLAIR):
 - Has a pretreatment serum total IgE measurement of: _____

6. For treatment of ALL OTHER DIAGNOSES:

- List other treatments tried (including start/stop dates, dose, outcomes): _____

RENEWAL REQUESTS

1. For treatment of ASTHMA:

- Experienced measurable evidence of improvement in the severity of the asthma condition
- Will continue to use optimally titrated doses of or has a contraindication or an intolerance to the following (check all that apply):
 - inhaled glucocorticoid
 - leukotriene modifier
 - long-acting beta-agonist (LABA)
 - other (e.g., tiotropium, theophylline): _____

2. For treatment of CHRONIC SPONTANEOUS (IDIOPATHIC) URTICARIA:

- Experienced an improvement in symptoms
- Document rationale for continued use: _____

3. For treatment of EGPA:

- Experienced measurable evidence of improvement in disease activity
- Reduction in use of systemic glucocorticoids for the treatment of EGPA

4. For treatment of HYPEREOSINOPHILIC SYNDROME (HES):

- Experienced measurable improvement in disease activity
- Reduction in use of systemic glucocorticoids for the treatment of HES

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature: _____ Date: _____

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.